What was known before {#section22-2054358119858014}
=====================

Rapid bone loss occurs in the first year postrenal transplantation but is a chronic disease. Existing systematic reviews identify a benefit of bisphosphonates in reducing bone mineral density (BMD) loss in the first 12 months posttransplant.

What this adds {#section23-2054358119858014}
==============

This current review adds there is no statistically significant benefit to bisphosphonate treatment on BMD beyond 1 year postrenal transplantation.

Introduction {#section24-2054358119858014}
============

End-stage renal disease (ESRD) is associated with renal osteodystrophy (osteitis fibrosa, adynamic bone disease, and osteomalacia).^[@bibr1-2054358119858014][@bibr2-2054358119858014][@bibr3-2054358119858014]-[@bibr4-2054358119858014]^ A well-functioning renal allograft ameliorates many metabolic abnormalities associated with the development of mineral and bone disorders (MBDs) of ESRD. However, renal transplant recipients are particularly susceptible to bone damage due to a multitude of factors including preexisting bone disorders, immunosuppression, and alteration in the renal-bone metabolism axis.^[@bibr5-2054358119858014],[@bibr6-2054358119858014]^

Bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DEXA) has been shown to decrease below 2 standard deviations (SDs) posttransplantation,^[@bibr7-2054358119858014]^ with estimated 3%-7% loss in the lumbar spine in the first year.^[@bibr8-2054358119858014][@bibr9-2054358119858014][@bibr10-2054358119858014]-[@bibr11-2054358119858014]^ Ongoing vertebral bone loss (approximately 2%/yr) has been demonstrated in longitudinal evaluation of BMD in 70 renal transplant recipients.^[@bibr12-2054358119858014]^

There are few studies demonstrating that low BMD predicts fractures in renal recipients. Akaberi et al^[@bibr13-2054358119858014]^ showed that low hip BMD predicted fractures in 238 renal recipients. The prevalence of fractures in the posttransplant population is up to 4-fold greater than pretransplant statistics, ranging widely between 5% and 44%, likely due to variations in observation time, definitions of fractures included, and the presence of diabetes.^[@bibr14-2054358119858014][@bibr15-2054358119858014][@bibr16-2054358119858014]-[@bibr17-2054358119858014]^

There is currently no established strategy for the prevention of posttransplant osteopenia and osteoporosis. Bisphosphonates, which inhibit osteoclast activity, are widely accepted as a treatment for osteopenia and osteoporosis in the general population.^[@bibr18-2054358119858014]^ They have also been shown to protect against bone loss in the renal transplant recipients,^[@bibr1-2054358119858014],[@bibr7-2054358119858014],[@bibr19-2054358119858014],[@bibr20-2054358119858014]^ although a specific risk is the potential to exacerbate a baseline low-turnover adynamic state.^[@bibr1-2054358119858014],[@bibr21-2054358119858014],[@bibr22-2054358119858014]^

The currently available research on bisphosphonate use in the renal transplant population is limited to analysis of randomized clinical trial (RCTs) within the first year posttransplant^[@bibr18-2054358119858014],[@bibr23-2054358119858014][@bibr24-2054358119858014]-[@bibr25-2054358119858014]^ The first year posttransplant is wrought with confounding factors including the physiologic adjustments in metabolism, the uremic effects of ESRD, the fluctuant nature of the posttransplant course, and aggressive immunosuppression.

Our study aimed to systematically review and meta-analyze the current literature on the use of any bisphosphonate in the adult renal transplant population beyond the first year of renal transplant to determine its effect on BMD and fracture incidence.

Methods {#section25-2054358119858014}
=======

Eligibility Criteria {#section26-2054358119858014}
--------------------

We conducted a systematic review and meta-analysis of primary research literature that included full-text, English-language, original RCTs and observational studies. Our population of interest was patients older than 18 years who received deceased/living donor kidney transplantation and any bisphosphonate with a follow-up greater than 12 months posttransplantation ([Figure 1](#fig1-2054358119858014){ref-type="fig"}). [Supplemental Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014) summarizes the inclusion and exclusion criteria of our review.

![Summary of study timelines in postrenal transplant patients on bisphosphonate therapy.\
*Note.* BMD = bone mineral density.](10.1177_2054358119858014-fig1){#fig1-2054358119858014}

Search Strategy {#section27-2054358119858014}
---------------

Electronic searches were performed in MEDLINE, EMBASE, and the Cochrane Register of Controlled Trials (CENTRAL) between 1946 and 2017 ([Figure 2](#fig2-2054358119858014){ref-type="fig"}). A sample search strategy is outlined in [Supplemental Figure 1](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014).

![Schema of literature search.](10.1177_2054358119858014-fig2){#fig2-2054358119858014}

Data Extraction and Outcome Measures {#section28-2054358119858014}
------------------------------------

Each included study was assessed in conjunction by 2 authors (A.L. and A.W.) for data extraction ([Tables 1](#table1-2054358119858014){ref-type="table"}[](#table2-2054358119858014){ref-type="table"}[](#table3-2054358119858014){ref-type="table"}-[4](#table4-2054358119858014){ref-type="table"}). The primary outcome was the change in BMD from baseline. The secondary outcomes were the incidence of fractures and the effects of other confounders that may modify the risk of osteoporosis and fractures.

###### 

Duration of Bisphosphonate Therapy and Follow-up in Postrenal Transplant Patients.

![](10.1177_2054358119858014-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                Treatment                                                                                                                                                       Concomitant treatment                                                             Treatment start date                                      Treatment duration                                      Time of outcome analysis from treatment initiation
  ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------
  Sánchez-Escuredo et al^[@bibr26-2054358119858014]^   Oral ibandronate 150 mg monthly (n = 35)\                                                                                                                       CaCO~3~ 2500 mg\                                                                  At least 12 months posttransplant                         12 months                                               12 months
                                                       Control: Oral risedronate 35 mg weekly (n = 34)                                                                                                                 Vitamin D 800 IU                                                                                                                                                                                    

  Okamoto et al^[@bibr27-2054358119858014]^            Oral alendronate 35 mg per week (n = 5)\                                                                                                                        Not specified                                                                     At least 12 months posttransplant                         24 months                                               24 months
                                                       Control: no bisphosphonates (n = 7)                                                                                                                                                                                                                                                                                                                                 

  Walsh et al^[@bibr28-2054358119858014]^              IV pamidronate 1 mg/kg within 14 days of transplant and 1, 4, 8, and 12 months after transplant (n = 46)\                                                       Calcium CaCO~3~ 500 mg\                                                           At transplantation                                        12 months                                               3, 6, 12, and 24 months
                                                       Control: no intervention (n = 47)                                                                                                                               Cholecalciferol 400 IU                                                                                                                                                                              

  Lan et al^[@bibr29-2054358119858014]^                Alendronate 70 mg/wk for 6 months (n = 23)\                                                                                                                     CaCO~3~ 800 mg\                                                                   Treatment: 25.9 ± 10.6 months\                            6 months                                                6 months
                                                       Control: no intervention (n = 23)                                                                                                                               Calcitriol 0.25 µg\                                                               Control: 27.1 ± 12.4 months                                                                                       
                                                                                                                                                                                                                       for 6 months                                                                                                                                                                                        

  Schwarz et al^[@bibr30-2054358119858014]^            IV zoledronic acid 4 mg at 2 weeks and 3 months (n = 9)\                                                                                                        Calcium citrate 1000 mg daily for first 6 months                                  At time of transplantation                                2 doses---at 2 weeks and 3 months posttransplant        6 to 36 months
                                                       Control: placebo (n = 10)                                                                                                                                                                                                                                                                                                                                           

  Fan et al^[@bibr31-2054358119858014]^                IV pamidronate 0.5 mg/kg at the time of transplant and 1 month later (n = 9)\                                                                                   Not specified                                                                     At the time of transplantation                            2 doses---at the time of transplant and 1 month later   12 and 48 months
                                                       Control: 500 mL NS (n = 8)                                                                                                                                                                                                                                                                                                                                          

  Jeffery et al^[@bibr32-2054358119858014]^            Alendronate 10 mg/d open label (n = 57; 46 completed 1 year)\                                                                                                   Calcium 500 mg/d                                                                  102 ± 80.4 months (8.5 ± 6.7 years) posttransplantation   12 months                                               12 months
                                                       Control: Calcitriol 0.25 µg/d (n = 60; 51 completed 1 year)                                                                                                                                                                                                                                                                                                         

  Koc et al^[@bibr33-2054358119858014]^                1: Alendronate 10 mg/d (n = 8)\                                                                                                                                 Calcium 1000 mg/d                                                                 Minimum duration of renal transplant was 12 months        Study period: 12 months                                 12 months
                                                       2: Calcitriol 0.5 µg/d (n = 8)\                                                                                                                                                                                                                                                                                                                                     
                                                       Control: no intervention (n = 8)                                                                                                                                                                                                                                                                                                                                    

  Tillmann et al^[@bibr34-2054358119858014]^           IV ibandronate 3 mg every 3 months (average dose 12.0 ± 6.7 g) (n = 30)\                                                                                        Not specified                                                                     51.0 ± 61.4 months after transplant\                      Average 19.3 ± 11 months                                26.8 ± 12.1 months after first measurement
                                                       Control: No intervention (n = 30)                                                                                                                                                                                                                 First BMD measured at minimum 14 months posttransplant                                                            

  Naylor et al^[@bibr35-2054358119858014]^             Unspecified bisphosphonate, grouped into "osteoporosis treatment"---includes \>90% bisphosphonate, nasal calcitonin, raloxifene, systemic estrogen (n = 329)\   ---                                                                               ---                                                       ---                                                     Mean 98.4 months (8.2 years) follow-up from study start
                                                       No comparator                                                                                                                                                                                                                                                                                                                                                       

  Yamamoto et al^[@bibr36-2054358119858014]^           Oral alendronate 35 mg/wk (n = 24)\                                                                                                                             Not specified                                                                     129.6 ± 40.8 months\                                      36 months treatment period                              12 and 24 months
                                                       No control group                                                                                                                                                                                                                                  (10.8 ± 3.4 years) posttransplant                                                                                 

  Huang et al^[@bibr37-2054358119858014]^              Alendronate 70 mg/wk (n = 41)\                                                                                                                                  Not specified                                                                     At least 5 months posttransplantation                     Duration of treatment unclear                           14 ± 1.6 months
                                                       Control: no intervention (n = 35)                                                                                                                                                                                                                                                                                                                                   

  Conley et al^[@bibr38-2054358119858014]^             Bisphosphonate as prescribed by treating physician (n = 315)\                                                                                                   Intervention:\                                                                    12 months posttransplant                                  Treatment duration not specified                        Not consistent
                                                       Control: no intervention (n = 239)                                                                                                                              Calcium = 170 (71.1%)\                                                                                                                                                                              
                                                                                                                                                                                                                       Vitamin D = 35 (14.6%)\                                                                                                                                                                             
                                                                                                                                                                                                                       Active vitamin D = 11 (4.6%)\                                                                                                                                                                       
                                                                                                                                                                                                                       Control:\                                                                                                                                                                                           
                                                                                                                                                                                                                       Calcium = 220 (69.8%)\                                                                                                                                                                              
                                                                                                                                                                                                                       Vitamin D = 83 (26.3%)\                                                                                                                                                                             
                                                                                                                                                                                                                       Active vitamin D = 39 (12.4%)                                                                                                                                                                       

  Ahn et al^[@bibr39-2054358119858014]^                Oral alendronate sodium or risedronate sodium (dose not specified)\                                                                                             Calcium (dose not specified)                                                      In study group, within 1 month of transplant              Treatment duration not specified                        12, 24, and 36 months posttransplant
                                                       Control: alfacalcidol (dose not specified)\                                                                                                                                                                                                                                                                                                                         
                                                       (n = 294, total)                                                                                                                                                                                                                                                                                                                                                    

  Cruz et al^[@bibr40-2054358119858014]^               Oral alendronate 10 mg/d (n = 29, high risk)\                                                                                                                   None                                                                              12 months posttransplant                                  Study period: 12 months                                 12 months
                                                       Control: no intervention (n = 28, low risk)                                                                                                                                                                                                                                                                                                                         

  Arlen et al^[@bibr41-2054358119858014]^              Oral etidronate disodium 400 mg for 2 weeks of every 12 weeks (n = 25)\                                                                                         Calcium replacement and Vitamin D at the discretion of the treating physicians\   Treatment: 10.4 ± 5.3 months after transplant\            Study period: 12 months                                 12 months
                                                       Control: no intervention (n = 24)                                                                                                                               Patients held medication during the 2 weeks of treatment\                         Control: 10.7 ± 4.5 months                                                                                        
                                                                                                                                                                                                                       Intervention:\                                                                                                                                                                                      
                                                                                                                                                                                                                       CaCO~3~ (n = 3) Calcitriol (n = 4)\                                                                                                                                                                 
                                                                                                                                                                                                                       Control:\                                                                                                                                                                                           
                                                                                                                                                                                                                       CaCO~3~ (n = 3) Calcitriol (n = 8)                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* IU = international unit; IV = intravenous; NS = normal saline; BMD = bone mineral density. White is RCT, Grey shaded region is Observational trials.

###### 

Baseline Characteristics of Included Studies.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Year   Population (male/female)        Mean age (mean ± SD)                                                                                         Time after transplant                                                 Intervention                                                                    Comparator                                   Funding support
  --------------------------- ------ ------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------
  Randomized control trials                                                                                                                                                                                                                                                                                                                                                          

   Sánchez-Escuredo et al     2015   77\                             Ibandronate: 63 ± 12\                                                                                        Ibandronate: 20 ± 8 months\                                           Ibandronate 150 mg/month\                                                       Risedronate 35 mg/wk\                        NA
                                     (19/58)                         Risedronate: 64 ± 10                                                                                         Risedronate: 18 ± 7 months                                            Vitamin D 800 IU\                                                               Vitamin D 800 IU\                            
                                                                                                                                                                                                                                                        CaCO~3~ 2500 mg\                                                                CaCO~3~ 2500 mg\                             
                                                                                                                                                                                                                                                        (n = 38)                                                                        (n = 39)                                     

   Okamoto et al              2014   12\                             Alendronate: 52.8 ± 12.6\                                                                                    Alendronate: 59.6 ± 59.5 months\                                      Alendronate 35 mg/wk for 24 months\                                             No intervention\                             MSD K.K.
                                     (8/4)                           Control: 52.9 ± 7.3                                                                                          Control: 45.3 ± 42.3 months                                           (n = 5)                                                                         (n = 7)                                      

   Walsh et al                2009   93\                             Treatment: 46.1 ± 12.77\                                                                                     0                                                                     Pamidronate IV 1 mg/kg peri-op, 1, 4, 8 and 12 months\                          CaCO~3~ 500 mg\                              Novartis
                                     (69/24)                         Control: 46.1 ± 12.93                                                                                                                                                              CaCO~3~ 500 mg\                                                                 Cholecalciferol 400 units\                   
                                                                                                                                                                                                                                                        Cholecalciferol 400 units\                                                      (n = 47)                                     
                                                                                                                                                                                                                                                        (n = 46)                                                                                                                     

   Lan et al                  2008   46\                             Treatment: 40.2 ± 18.5\                                                                                      Treatment: 25.9 ± 10.6 months\                                        Alendronate 70 mg/wk\                                                           CaCO~3~ 800 mg/d\                            Not reported
                                     (19/27)                         Control: 39.4 ± 17.3                                                                                         Control: 27.1 ± 12.4 months                                           CaCO~3~ 800 mg/d\                                                               Calcitriol 0.25 µg/d\                        
                                                                                                                                                                                                                                                        Calcitriol 0.25 µg/d\                                                           (n = 23)                                     
                                                                                                                                                                                                                                                        (n = 23)                                                                                                                     

   Schwartz et al             2004   19\                             Not reported                                                                                                 0                                                                     Two infusions of 4 mg zoledronic acid at 2 weeks and 3 months posttransplant\   Placebo\                                     Not reported
                                     (not reported)                                                                                                                                                                                                     (n = 9)                                                                         (n = 10)                                     

   Fan et al                  2003   I26\                            Treatment: 46.2 (21.1-67.1)\                                                                                 Not reported                                                          Pamidronate IV 0.5 mg/kg in 500 mL NS peri-op and at 1 month\                   500 mL NS\                                   Not reported
                                     (26/0)                          Control: 41.5 (21.3-65)\                                                                                                                                                           (n = 14)                                                                        (n = 12)                                     
                                                                     Mean age calculated with only patients with BMD measurements at 4 years                                                                                                                                                                                                                                         

   Jeffrey et al              2003   117 (97 completed treatment)\   Treatment: 44.8 ± 11.6\                                                                                      Treatment: 85.2 ± 62.4 months\                                        Alendronate 10 mg/d open label\                                                 Calcitriol 0.25 µg/d\                        Not reported
                                     (71/26)                         Control: 45.9 ± 10.8\                                                                                        Control:\                                                             Calcium (*unspecified dose*)\                                                   Calcium (*unspecified dose*)\                
                                                                     Mean age documented is at the time of transplant and calculated with only patients who completed treatment   115.2 ± 81.6 months\                                                  (n = 60) 46 completed treatment                                                 (n = 57) 51 completed treatment              
                                                                                                                                                                                  Mean duration calculated with only patients who completed treatment                                                                                                                                

   Koc et al                  2002   24\                             Alendronate: 34.3 ± 8.9\                                                                                     Alendronate: 48.7 ± 50.1 months\                                      I1: Alendronate 10 mg/d\                                                        Calcium 1000 mg/d\                           Not reported
                                     (17/7)                          Calcitriol: 40.5 ± 8.1\                                                                                      Calcitriol: 47.4 ± 46.4 months\                                       Calcium 1000 mg/d\                                                              (n = 8)                                      
                                                                     Control: 35.5 ± 8.4                                                                                          Control: 41.5 ± 37.1 months                                           (n = 8)\                                                                                                                     
                                                                                                                                                                                                                                                        I2: Calcitriol 0.5 µg/d\                                                                                                     
                                                                                                                                                                                                                                                        Calcium 1000 mg/d\                                                                                                           
                                                                                                                                                                                                                                                        (n = 8)                                                                                                                      

  Observational studies                                                                                                                                                                                                                                                                                                                                                              

   Naylor et al               2014   326\                            46.1 ± 12                                                                                                    6.12 (2.4-24) months                                                  \>90% bisphosphonates, nasal calcitonin, raloxifene, systemic estrogen          No control group                             NA
                                     (199/27)                                                                                                                                                                                                                                                                                                                                        

   Yamamoto et al             2013   24\                             52 ± 7.8                                                                                                     129.6 ± 40.8 months                                                   Alendronate 35 mg/d                                                             No control group                             NA
                                     (12/12)                                                                                                                                                                                                                                                                                                                                         

   Huang et al                2012   76\                             Treatment:\                                                                                                  Treatment:\                                                           Alendronate 70 mg/wk\                                                           No intervention\                             NA
                                     (36/40)                         Male: −51.9 ± 9.0\                                                                                           Male: −103.7 ± 59.4\                                                  (n = 34)                                                                        (n = 42)                                     
                                                                     Female: −53.3 ± 8.8\                                                                                         Female: −53.3 ± 8.8\                                                                                                                                                                               
                                                                     Control:\                                                                                                    Control:\                                                                                                                                                                                          
                                                                     Male: −48 ± 10.4\                                                                                            Male: −92 ± 68.1\                                                                                                                                                                                  
                                                                     Female: −49.7 ± 7.6                                                                                          Female: −61.4 ± 39.6                                                                                                                                                                               

   Conley et al               2008   554\                            Treatment: 45.9 ± 0.7\                                                                                       Not reported                                                          Bisphosphonate, type not described\                                             Calcium = 220 (69.8) (NS)\                   Not reported
                                     (320/234)                       Control: 46.9 ± 0.2                                                                                                                                                                Calcium = 170 (71.1), Vitamin D = 35 (14.6), Active vitamin D = 11 (4.6)\       Vitamin D = 83 (26.3) (*P* = .001)\          
                                                                                                                                                                                                                                                        (n = 315)                                                                       Active vitamin D = 39 (12.4) (*P* = .003)\   
                                                                                                                                                                                                                                                                                                                                        (n = 239)                                    

   Ahn et al                  2006   294                             Not reported                                                                                                 Within 1 month                                                        Calcium\                                                                        No intervention                              Not reported
                                                                                                                                                                                                                                                        Alfacalcidol or bisphosphonate (alendronate or risendronate)                                                                 

   Cruz et al                 2002   58\                             Treatment: 48.6 ± 2.0\                                                                                       Treatment: 97.2 ± 8.4 months\                                         Alendronate 10 mg/d\                                                            No intervention\                             NCRR grant, National Kidney Foundation of Connecticut, NIH
                                     (39/19)                         Control: 46.2 ± 2.0                                                                                          Control: 84 ± 10.8 months                                             (n = 29)                                                                        (n = 29)                                     

   Arlen et al                2001   49\                             Treatment: 41 ± 13\                                                                                          Treatment: 10.4 ± 5.2 months\                                         Etidronate disodium 400 mg for 2 weeks out of every 12\                         No intervention\                             Not reported
                                     (29/20)                         Control: 42 ± 12                                                                                             Control: 10.8 ± 4.5 months                                            CaCO~3~ (n = 3)\                                                                CaCO~3~ (n = 3)\                             
                                                                                                                                                                                                                                                        Calcitriol (n = 4)\                                                             Calcitriol (n = 8, *P* \< .03)\              
                                                                                                                                                                                                                                                        (n = 25)                                                                        (n = 24)                                     

   Tillmann et al             2001   60\                             Treatment: 47.9 ± 13.4\                                                                                      Treatment: 51 ± 61.4 months\                                          Ibandronate 3 mg IV Q3 months\                                                  No intervention\                             None
                                     (24/36)                         Control: 45.7 ± 11.4\                                                                                        Control\                                                              (n = 30)                                                                        (n = 30)                                     
                                                                     Mean age documented is at the time of transplant                                                             59.6 ± 59.7 months                                                                                                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* IU = international unit; NA = not applicable; IV = intravenous; BMD = bone mineral density; NS = normal saline; NCRR = National Center for Research Resources; NIH = National Institutes of Health.

###### 

Change in Bone Mineral Density in Postrenal Transplant Patients Between Bisphosphonate and Control Groups.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                 BMD                                                                                                                                                                         
  ----------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  Sánchez-Escuredo et al^[@bibr26-2054358119858014]^\   T-score at pretreatment/12 months\                                                 T-score at pretreatment/12 months\                                                       
  I1: n = 35\                                           I1: −1.7 ± 0.8/−1.4 ± 0.6\                                                         I1: −2.1 ± 0.7/−1.8 ± 0.9\                                                               
  I2: n = 34                                            I2 −1.9 ± 0.8/−1.5 ± 0.8                                                           I2: −2.2 ± 0.6/−1.8 ± 0.8                                                                

  Okamoto et al^[@bibr27-2054358119858014]^\            NA                                                                                 NA                                                                                       Total BMD:\
  I: n = 5\                                                                                                                                                                                                                         % change from baseline\
  C: n = 7                                                                                                                                                                                                                          I: 1.86% ± 0.85%, *P* \< .05\
                                                                                                                                                                                                                                    *No other raw data provided*

  Walsh et al^[@bibr28-2054358119858014]^\              \% change in BMD at 12 months from baseline\                                       \% change in BMD at 12 months from baseline\                                             Ward's area:\
  I: n = 46\                                            AMTD: 7.78%, 95% CI: 5.15-10.41, *P* \< .001\                                      AMTD: 2.51%, 95% CI: −0.33 to 5.35, *P* = .08\                                           Significant increase in I vs C at both 12 and 24 months\
  C: n = 47                                             Significant difference between groups at 24 months\                                No significant difference between groups at 24 months\                                   AMTD: 5.83%, 95% CI: 2.19-9.45, *P* \< .01\
                                                        *No raw data*                                                                      *No raw data*                                                                            Total hip:\
                                                                                                                                                                                                                                    Significant increase in I vs C at both 12 and 24 months\
                                                                                                                                                                                                                                    AMTD: 2.79%, 95% CI: 0.92-4.67, *P* \< .01

  Lan et al^[@bibr29-2054358119858014]^\                Mean g/cm^2^ at pretreatment/6 months\                                             Mean g/cm^2^ at pretreatment/6 months\                                                   Trochanter:\
  I: n = 23\                                            I: (L1) 0.781 ± 0.117/0.820 ± 0.114, NS\                                           I: 0.650 ± 0.107/0.731 ± 0.109, *P* \< .05\                                              Mean g/cm^2^ at pretreatment/6 months\
  C: n = 23                                             C: (L1) 0.760 ± 0.062/0.771 ± 0.069, NS                                            C: 0.657 ± 0.061/0.676 ± 0.060, NS\                                                      I: 0.524 ± 0.093/ 0.572 ± 0.103, NS\
                                                                                                                                           Significant difference between groups at 6 months posttreatment,*P* \< .05               C: 0.54 ± 0.082/ 0.561 ± 0.079, NS

  Schwarz et al^[@bibr30-2054358119858014]^\            Z-score at 6 months to 32 months posttreatment\                                    Z-score at 6 months to 32 months posttreatment\                                          
  I: n = 9\                                             I: No difference\                                                                  I: −1.6 (2.9) to −1.2 (1.9), *P* \< .05\                                                 
  C: n = 10                                             C: No difference\                                                                  between groups, *P* \< .05\                                                              
                                                        NS between groups\                                                                 C: −1.3 (2.6) to −0.2 (3.6), *P* \< .05\                                                 
                                                        No raw data                                                                        between groups, *P* \< .05\                                                              
                                                                                                                                           median and range                                                                         

  Fan et al^[@bibr31-2054358119858014]^\                Mean g/cm^2^ at baseline/1 year/4 years\                                           Mean g/cm^2^ at baseline/1 year/4 years\                                                 
  I: n = 9\                                             I: 1.15 ± 0.07/(1 year) 1.11 ± 0.05, NS/(4 years) 1.10 ± 0.04, NS\                 I: 0.93 ± 0.05/(1 year) 0.94 ± 0.04, NS/(4 years) 0.88 ± 0.04, NS\                       
  C: n = 8                                              C: 1.27 ± 0.07/(1 year) 1.2 ± 0.5, *P* \< .05/(4 years) 1.21 ± 0.08, NS            C: 1.08 ± 0.07/ (1 year) 0.98 ± 0.06, *P* \< .05/(4 years) 0.94 ± 0.06, *P* \< .01       

  Jeffery et al^[@bibr32-2054358119858014]^\            Mean g/cm^2^ at pretreatment/12 months\                                            Mean g/cm^2^ at pretreatment/12 months\                                                  
  I: n = 57\                                            I: 0.984 ± 0.149/1.025 ± 0.143, *P* \< .001\                                       I: 0.809 ± 0.092/0.836 ± 0.107, *P* \< .001\                                             
  C: n = 60                                             C: 1.014 ± 0.15/1.034 ± 0.146, *P* \< .01\                                         C: 0.830 ± 0.144/0.857 ± 0.125, *P* \< .05\                                              
                                                        NS between groups at 12 months (*P* = .082)                                        NS between groups at 12 months (*P* = .96)                                               

  Koc et al^[@bibr33-2054358119858014]^\                Mean g/cm^2^ at 12 months/pretreatment\                                            Mean g/cm^2^ at 12 months/pretreatment\                                                  
  I1: n = 8\                                            I1: 1.050 ± 0.086/1.122 ± 0.094, *P* \< .01\                                       I1: 0.826 ± 0.121/ 0.902 ± 0.092, *P* \< .05\                                            
  I2: n = 8\                                            I2: 0.963 ± 0.142/ 1.034 ± 0.119, *P* \< .05\                                      I2: 0.816 ± 0.121/0.902 ± 0.092, NS\                                                     
  C: n = 8                                              C: 1.082 ± 0.187/1.095 ± 0.142, NS\                                                C: 0.933 ± 0.082/0.947 ± 0.082, NS\                                                      
                                                        % change of BMD\                                                                   % change of BMD\                                                                         
                                                        I1: 8.15% ± 9.2%\                                                                  I1: 9.34 ± 10.47%\                                                                       
                                                        I2: 6.89% ± 4.03%\                                                                 I2: 8.51 ± 13.8%\                                                                        
                                                        C: 0.06% ± 1.41%\                                                                  C: 1.92 ± 2.52%\                                                                         
                                                        *P* \< .05 compared with control                                                   NS compared with control                                                                 

  Tillmann et al^[@bibr34-2054358119858014]^\           Z-score at pre-treatment/26.8 ± 12.1 months\                                       Z-score at pretreatment/26.8 ± 12.1 months\                                              
  I: n = 30\                                            I: −2.25 ± 1.11/−1.78 ± 1.30, *P* \< .05\                                          I: −1.97 ± 0.85/−1.73 ± 0.71, *P* \< .05\                                                
  C: n = 30                                             C: −0.52 ± 1.52/−0.28 ± 1.55, *P* \< .05\                                          C: −0.69 ± 1.31/−0.55 ± 1.12, *P* \< .05\                                                
                                                        Change in BMD\                                                                     Change in BMD\                                                                           
                                                        I: 0.055 ± 0.066\                                                                  I: 0.025 ± 0.077\                                                                        
                                                        C: 0.033 ± 0.079\                                                                  C: 0.013 ± 0.106\                                                                        
                                                        NS between groups, *P* = .217                                                      NS between groups, *P* = .647                                                            

  Naylor et al^[@bibr35-2054358119858014]^\             Z-score\                                                                           Z-score\                                                                                 Hip Z-score\
  n = 329                                               −0.4 ± 1.6\                                                                        −0.7 ± 1.1\                                                                              −0.7 ± 1.1\
                                                        At median 6 months (baseline)\                                                     At median 6 months (baseline)\                                                           At median 6 months (baseline)\
                                                        −0.2 ± 1.6, *P* \< .001 vs baseline\                                               −0.6 ± 1, *P* \< .01 vs baseline\                                                        −0.6 ± 1.1, *P* \< .01 vs baseline\
                                                        At mean 2.7 years\                                                                 At mean 2.7 years\                                                                       At mean 2.7 years\
                                                        +0.5 ± 1.5, *P* \< .001 vs baseline\                                               +0.1 ± 1.5, *P* \< .001 vs baseline\                                                     −0.5 ± 1.1, *P* \< .001 vs baseline\
                                                        At mean 8.2 years                                                                  At mean 8.2 years                                                                        At mean 8.2 years

  Yamamoto et al^[@bibr36-2054358119858014]^\           Mean g/cm^2^ pretreatment/12 months/24 months\                                                                                                                              
  n = 24                                                (Baseline) 0.80 ± 0.11/(12-month) 0.78 ± 0.12, NS/(24-month) 0.79 ± 0.15, NS                                                                                                

  Huang et al^[@bibr37-2054358119858014]^\              For 76 included patients\                                                          T-score at pretreatment/14 ± 1.6 months\                                                 Hip:\
  I: n = 34\                                            T-score at pretreatment/14 ± 1.6 months\                                           −2.45 ± 0.96/−2.42 ± 1.02, NS\                                                           T-score at pretreatment/14 ± 1.6 months\
  C: n = 42                                             −1.53 ± 1.24/−1.32 ± 1.26, *P* \< .001\                                            BMD: Mean g/cm^2^ at pretreatment/14 ± 1.6 months\                                       −1.76 ± 0.97/−1.68 ± 1.07, NS\
                                                        BMD: Mean g/cm^2^ at pretreatment/14 ± 1.6 months\                                 0.68 ± 0.12/ 0.69 ± 0.13, NS                                                             BMD: Mean g/cm^2^ at pretreatment/14 ± 1.6 months\
                                                        0.90 ± 0.14/0.92 ± 0.14, *P* = .001                                                                                                                                         0.81 ± 0.14/0.81 ± 0.14, NS

  Conley et al^[@bibr38-2054358119858014]^\             T-score at mean 1.2 ± 0.05 years posttransplant/2.5 ± 0.05 years posttransplant\   T-score at mean 1.2 ± 0.05 years posttransplant/2.5 ± 0.05 years posttransplant\         
  I: n = 315\                                           I: −1.4 ± 1.3/−1.0 ± 1.3\                                                          I: −1.9 ± 1/−1.7 ± 1\                                                                    
  C: n = 239                                            C: 1.3 ± 0.5/0 ± 1.4\                                                              C: 1.0 ± 0/−1.0 ± 1.0\                                                                   
                                                        *P* \< .001 between groups                                                         *P* \< .001 between groups                                                               

  Ahn et al^[@bibr39-2054358119858014]^\                Mean different in T-score at 12, 24, and 36 months compared with baseline\         Mean different in T-score at 12, 24 and 36 months compared with baseline\                
  n = 294                                               1 year C/I:\                                                                       1 year C/I:\                                                                             
                                                        −0.51 ± 0.66/−0.13 ± 0.73, *P* \< .05 (n = 275/19)\                                −0.22 ± 0.69/0.13 ± 0.55, *P* \< .05 (n = 273/19)\                                       
                                                        2 year C/I:\                                                                       2 year C/I:\                                                                             
                                                        −0.76 ± 0.74/−0.4 ± 0.79, *P* \< .05 (n = 151/45)\                                 −0.38 ± 0.82/−0.1 ± 0.77, *P* = .20 (n = 150/44)\                                        
                                                        3 year C/I:\                                                                       3 year C/I:\                                                                             
                                                        −0.83 ± 0.83/−0.5 ± 0.8, *P* = .10 (n = 74/32)                                     −0.43 ± 0.85/0.20 ± 0.94, *P* = .21 (n = 75/31)                                          

  Cruz et al^[@bibr40-2054358119858014]^\               T-score at pretreatment/12 months\                                                 T-score at pretreatment/12 months\                                                       Total femur:\
  I: n = 29\                                            I: −1.71 ± 0.19/*no raw data* result\                                              I: −1.43 ± 0.13/−1.34 ± 0.14(*P* \< .01) (change in T-score +1.6 ± 0.6%, *P* \< .001)\   T-score at pretreatment/12 months\
  C: n = 28                                             (change in T-score: + 3.4% ± 0.6%, *P* \< .001)\                                   C: −1.10 ± 0.15/*no raw data result*                                                     I: −1.43 ± 0.13/−1.34 ± 0.14 (*P* \< .01) (change in T-score: +1.6 ± 0.6%, *P* \< .001)\
                                                        C: −0.70 ± 0.24/*no raw data result*                                                                                                                                        C: −0.67 ± 0.16/*no raw data result*

  Arlen et al^[@bibr41-2054358119858014]^\              Mean g/cm^2^ at pretreatment/23.3 ± 6.6 months\                                    Mean g/cm^2^ at pretreatment/23.3 ± 6.6 months (change in % BMD)\                        Trochanter:\
  I: n = 25\                                            I: 0.981 ± 0.138/1.021 ± 0.140\                                                    I: 0.784 ± 0.102/ 0.810 ± 0.110\                                                         Mean g/cm^2^ at pretreatment/23.3 ± 6.6 months (change in % BMD)\
  C: n = 24                                             C: 1.134 ± 0.168/1.143 ± 0.175\                                                    C: 0.867 ± 0.137/ 0.893 ± 0.147\                                                         I: 0.619 ± 0.094/0.683 ± 0.126\
                                                        Change in % BMD (I vs C)\                                                          Change in % BMD (I vs C)\                                                                C: 0.725 ± 0.116/ 0.738 ± 0.109\
                                                        4.3% ± 6.1% vs 0.55 ± 5.3%, *P* \< .05                                             3.4 ± 6.5% vs 3.2 ± 6.4% NS                                                              Change in % BMD (I vs C)\
                                                                                                                                                                                                                                    10.3 ± 11.9% vs 2.2 ± 5.7%, *P* \< .05
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* BMD = bone mineral density; I = intervention; C = control; n = number; AMTD = adjusted mean treatment difference; CI = confidence interval. White is RCT, Grey shaded region is Observational trials.

###### 

Fracture Incidence in Postrenal Transplant Patients Between Bisphosphonate and Control Groups.

![](10.1177_2054358119858014-table4)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                        Protocol                                                                              Baseline fractures                                                              New fracture incidence                                                          Findings                                                                                                                                  
  -------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------------------------------
  Walsh et al^[@bibr28-2054358119858014]^      Spine radiographs at baseline, 12, 24 months\                                         N = 23/93 total\                                                                                                                                                At 12 months                                                                                                               At 24 months   4.2% (−7.3 to 16.6) difference between groups at 12 months (*P* = .7)\
                                               Blinded interpretation using Genant et al^[@bibr42-2054358119858014]^ scale           12/46 in intervention group (1 axial)\                                                                                                                                                                                                                                                                    8.4% (−3.7 to 22.2) between groups at 24 months (*P* = .3)
                                                                                                                                     11/47 in control group                                                                                                                                                                                                                                                                                    

  I (n = 46):                                  2                                                                                     2\                                                                                                                                                                                                                                                                                                        
                                                                                                                                     (3.3%/yr)                                                                                                                                                                                                                                                                                                 

  C (n = 47):                                  4                                                                                     6\                                                                                                                                                                                                                                                                                                        
                                                                                                                                     (6.4%/yr)                                                                                                                                                                                                                                                                                                 

  Schwarz et al^[@bibr30-2054358119858014]^    Not formally assessed as endpoint                                                     Not assessed                                                                    Between 6 months and 3 years:\                                                  No analysis done                                                                                                                          
                                                                                                                                                                                                                     I (n = 9): 2 vertebral fractures\                                                                                                                                                                                         
                                                                                                                                                                                                                     C (n = 10): 2 vertebral fractures                                                                                                                                                                                         

  Yamamoto et al^[@bibr36-2054358119858014]^   Nontraumatic (low energy) fractures\                                                  N = 7/24\                                                                       4 patients with 5 fractures during 3-year period\                               New fractures correlated with higher intact PTH levels (pg/mL) at baseline:\                                                              
                                               Assessed via personal interviews and medical records                                  (4 wrist, 2 rib, 1 leg, 1 cuboidal)                                             (2 leg, 1 lumbar spine, 1 hip, 1 humeral)                                       Fracture (−) = 116.0 ± 52.6\                                                                                                              
                                                                                                                                                                                                                                                                                                     Fracture (−) = 255.0 ± 3.0 (*P* \< .0001)                                                                                                 

  Conley et al^[@bibr38-2054358119858014]^     Self-reported\                                                                        I: 56/315\                                                                      I: 16\                                                                          Treatment associated with decreased probability of fracture-free survival (HR = 0.40; 95% CI = 0.29-0.73, *P* = .001)\                    
                                               Counted if occurring between BMD1 and BMD2 (both occurring \>1 year posttransplant)   C: 16/239\                                                                      C: 7\                                                                           No association found between rate of bone loss and fractures, regardless of the bisphosphonate therapy                                    
                                                                                                                                     Significantly more patients with fracture in intervention group (*P* = .0002)   (*P* \< .05)\                                                                                                                                                                                                             
                                                                                                                                                                                                                     Increase in bone density between BMD1 and BMD2 did not prevent late fractures                                                                                                                                             

  Arlen et al^[@bibr41-2054358119858014]^      Not formally assessed as endpoint                                                     Not assessed                                                                    I (n = 25): n = 2\                                                              All patients who sustained fractures were from high-risk treatment group (BMD lower than mean baseline of control group)                  
                                                                                                                                                                                                                     C (n = 24): n = 1                                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Note.* I = intervention; C = control; BMD = bone mineral density; PTH = parathyroid hormone; HR = hazard ratio; CI = confidence interval. White is RCT, Grey shaded region is Observational trials.

Bias Assessment {#section29-2054358119858014}
---------------

Articles were independently assessed by each reviewer (A.L. and A.W.), and dichotomized to low/high risk of bias based on standardized scoring systems. An RCT was considered low risk if it satisfied a score of 8 or more based on the Cochrane Risk of Bias Tool Criteria ([Supplemental Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014)).^[@bibr43-2054358119858014]^ An observational trial was considered low risk if it satisfied a score of 3 or more based on the Newcastle-Ottawa Criteria ([Supplemental Table S3](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014)).^[@bibr44-2054358119858014]^

Statistical Analysis {#section30-2054358119858014}
--------------------

A standardized mean difference (SMD) and its 95% confidence interval (CI) were calculated to account for heterogeneity of different units of pre- and posttransplant measurements.^[@bibr45-2054358119858014]^ Using the 95% CIs, the SDs were then derived.^[@bibr46-2054358119858014]^ Subsequently, forest/funnel plots were created using the Cochrane Collaboration RevMan v5.3 software.^[@bibr46-2054358119858014]^ A random effects model was used to account for clinical heterogeneity of the meta-analyzed studies. Values of I^[@bibr2-2054358119858014]^ \>50% and *P* \< .10 were considered to indicate significant heterogeneity.

Results {#section31-2054358119858014}
=======

Description of the Search {#section32-2054358119858014}
-------------------------

The search strategy yielded 1084 articles between 1946 and 2017. All titles and abstracts were reviewed independently by 2 authors (A.L. and A.W.) in accordance with inclusion criteria ([Figure 2](#fig2-2054358119858014){ref-type="fig"}). Thirty-five articles were fully reviewed. Fourteen articles were differentially categorized between reviewers. These were independently reviewed and resolved by a third author (D.T.W.) to ascertain eligibility.

Description of Studies {#section33-2054358119858014}
----------------------

Sixteen studies met full inclusion criteria ([Table 1](#table1-2054358119858014){ref-type="table"}), including 8 randomized trials^[@bibr26-2054358119858014][@bibr27-2054358119858014][@bibr28-2054358119858014][@bibr29-2054358119858014][@bibr30-2054358119858014][@bibr31-2054358119858014][@bibr32-2054358119858014]-[@bibr33-2054358119858014]^ and 8 observational studies.^[@bibr34-2054358119858014][@bibr35-2054358119858014][@bibr36-2054358119858014][@bibr37-2054358119858014][@bibr38-2054358119858014][@bibr39-2054358119858014][@bibr40-2054358119858014]-[@bibr41-2054358119858014]^ Two RCTs^[@bibr28-2054358119858014],[@bibr30-2054358119858014]^ and 7 observational studies,^[@bibr34-2054358119858014][@bibr35-2054358119858014]-[@bibr36-2054358119858014],[@bibr38-2054358119858014][@bibr39-2054358119858014][@bibr40-2054358119858014]-[@bibr41-2054358119858014]^ were considered to have low risk of bias ([Supplemental Figures S2 and S3](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014)).

The total sample size was 1762 patients; 683 patients were treated with bisphosphonates while the remaining were allocated to various comparison groups. Bisphosphonates used included alendronate, alendronate/risedronate, pamidronate, zolendronate, ibandronate, and etidronate. Comparators included no therapy, calcium and/or vitamin D, calcitriol, placebo, an alternative bisphosphonate, and no control group. Baseline characteristic data of each study are summarized in [Table 2](#table2-2054358119858014){ref-type="table"}.

From the RCTs, 226 patients were prescribed a bisphosphonate with a concomitant treatment with Ca and/or vitamin D in 212 patients. Bisphosphonate-treatment duration ranged from 1 to 24 months, with a follow-up duration of 12 to 24 months ([Table 1](#table1-2054358119858014){ref-type="table"}). From the observational studies, 457 patients were prescribed a bisphosphonate. Of these patients, 223 had a concomitant treatment with Ca and/or vitamin D. Precise treatment was not clearly specified in an additional 624 patients. The range for bisphosphonate treatment was 12 to 36 months with a follow-up duration of 12 to 98.4 months ([Table 1](#table1-2054358119858014){ref-type="table"}).

BMD measurement was performed using DEXA in all studies, with results most often expressed as T-scores representing the number of SDs that the measurement falls from the mean of a young population. A T-score of −1 to −2.5 describes osteopenia and less than −2.5 is diagnostic of osteoporosis.^[@bibr47-2054358119858014]^ Results were also reported as bone mineral content or Z-scores that describe the number of SDs from the mean value of gender and age-matched adults (Z-score less than or equal to −2 suggests abnormal bone loss).

Change in BMD {#section34-2054358119858014}
-------------

### One year posttransplant {#section35-2054358119858014}

Thirteen studies demonstrated at least one site of improvement in BMD, while the other 3 studies^[@bibr30-2054358119858014],[@bibr32-2054358119858014],[@bibr36-2054358119858014]^ showed nonsignificant changes. However, only 2 studies^[@bibr28-2054358119858014],[@bibr39-2054358119858014]^ were able to capture patient data from the immediate peri-transplant period. At 12 months posttransplant, Walsh et al^[@bibr28-2054358119858014]^ identified a significant change in BMD in the intervention group vs control group, at the lumbar spine, +2.3% vs −5.7%, adjusted mean treatment difference (AMTD) 7.78%, *P* \< .001. T-scores were also significantly different in the intervention vs control group at both the lumbar spine (−0.13 ± 0.73 vs −0.51 ± 0.66, *P* \< .05) and the femoral neck (0.13 ± 0.55 vs −0.22 ± 0.69, *P* \< .05) at 12 months.^[@bibr39-2054358119858014]^ Both intervention groups showed significant improvement with bisphosphonate persisting into the second^[@bibr28-2054358119858014],[@bibr39-2054358119858014]^ and the third year^[@bibr39-2054358119858014]^ posttransplantation at the lumbar spine, with no significant difference at the femoral neck ([Table 3](#table3-2054358119858014){ref-type="table"}).

### One year postinitiation of bisphosphonate {#section36-2054358119858014}

Thirteen studies captured BMD data at least 12 months postinitiation of bisphosphonate treatment. Only 2 of these studies did not exhibit a significant increase in BMD^[@bibr32-2054358119858014]^ or Z-score^[@bibr30-2054358119858014]^ in the intervention vs control group in the lumbar spine at 12 and 32 months posttreatment.^[@bibr32-2054358119858014]^

Unlike the lumbar spine, all studies showed minimal change in BMD measurements at the femoral neck except for 3 studies^[@bibr31-2054358119858014],[@bibr33-2054358119858014],[@bibr39-2054358119858014]^ that showed a significant change ([Table 3](#table3-2054358119858014){ref-type="table"}). Result interpretation of the significantly different Z-scores between groups posttreatment was inconclusive in the study by Tillmann et al^[@bibr34-2054358119858014]^ as pretreatment measurements were also different. Cruz et al^[@bibr40-2054358119858014]^ also found different T-scores at the femoral neck posttreatment (change in T-score +1.6% ± 0.6%, *P* \< .001), but did not provide raw data of the control group to allow for comparison.

Using the calculated SMD between the intervention (bisphosphonate) and control groups, [Figures 3](#fig3-2054358119858014){ref-type="fig"} and [4](#fig4-2054358119858014){ref-type="fig"} summarize the study findings that include pre and postbisphosphonate treatment information on BMD, at the lumbar spine and femoral neck, respectively. Data from 4 RCTs^[@bibr29-2054358119858014],[@bibr31-2054358119858014][@bibr32-2054358119858014]-[@bibr33-2054358119858014]^ and 3 observational studies^[@bibr34-2054358119858014],[@bibr38-2054358119858014],[@bibr41-2054358119858014]^ were included in analysis. There is a nonsignificant improvement in BMD favoring the use of bisphosphonates, as evidenced at both the lumbar spine and femoral neck. There was no statistical heterogeneity noted when a random effects model was used. The funnel plot demonstrates reasonable dispersion ([Supplemental Figure S4](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014)).

![Change in bone mineral density at the lumbar spine in postrenal transplant patients between bisphosphonate and control groups.\
*Note.* CI = confidence interval.](10.1177_2054358119858014-fig3){#fig3-2054358119858014}

![Change in bone mineral density at the femoral neck in postrenal transplant patients between bisphosphonate and control groups.\
*Note.* CI = confidence interval.](10.1177_2054358119858014-fig4){#fig4-2054358119858014}

Fracture Incidence {#section37-2054358119858014}
------------------

Fracture incidence was low but only reported in 5 studies^[@bibr28-2054358119858014],[@bibr30-2054358119858014],[@bibr36-2054358119858014],[@bibr38-2054358119858014],[@bibr41-2054358119858014]^ with a total of 43 new fractures. Conley et al^[@bibr38-2054358119858014]^ reported benefit from bisphosphate treatment and decreased fracture rates (hazard ratio \[HR\] = 6.7, 95% CI = 6-6284, *P* \< .01), despite only a small subset of patients (n = 3) with baseline osteoporosis at the femoral neck. Conley et al^[@bibr38-2054358119858014]^ noted that bisphosphonate treatment was associated with decreased probability of fracture-free survival (HR = 0.40, 95% CI = 0.29-0.73, *P* = .001) in the initial analysis, even though treatment was associated with significant reduction in bone loss at the femoral neck (HR = 1.56, 95% CI = 1.21-2.06, *P* \< .001) and lumbar spine (HR = 1.48, 95% CI = 1.13-1.98, *P* \< .01). However, after adjusted analysis, no association was identified between bone loss and fractures regardless of the bisphosphonate treatment.^[@bibr38-2054358119858014]^

Confounding Factors Affecting BMD {#section38-2054358119858014}
---------------------------------

### Immunosuppression {#section39-2054358119858014}

Four studies^[@bibr32-2054358119858014],[@bibr35-2054358119858014],[@bibr37-2054358119858014],[@bibr39-2054358119858014]^ examined the effects of steroids on bone health. At baseline, patients with osteoporosis received a greater cumulative steroid dose than patients with osteopenia (1326.5 mg vs 724.5 mg; *P* \< .01).^[@bibr37-2054358119858014]^ In a univariate analysis, prednisolone use was associated with osteoporosis (odds ratio \[OR\] = 5.18; 95% CI = 1.6-16.4, *P* \< .01).^[@bibr37-2054358119858014]^ Jeffery et al^[@bibr32-2054358119858014]^ described prednisone as an independent predictor of low BMD (multivariate, *P* \< .01). Alternatively, Naylor et al^[@bibr35-2054358119858014]^ found greater glucocorticoid exposure was not associated with a significant change in BMD at the lumbar spine, total hip, and femoral neck (*P* \> .05), regardless of whether the patient had received osteoporosis treatment before. Similarly, no BMD differences were observed, 1 year posttransplant, in recipients receiving steroids.^[@bibr39-2054358119858014]^ The effects of cyclosporine on BMD were examined in 2 studies^[@bibr37-2054358119858014],[@bibr39-2054358119858014]^ and demonstrated no effects up to 1 year posttransplant.

### Body mass index {#section40-2054358119858014}

Three studies^[@bibr32-2054358119858014],[@bibr35-2054358119858014],[@bibr39-2054358119858014]^ found that low body weight (*P* \< .001) and body mass index (BMI) (*P* \< .01) were correlated with reduced lumbar and femoral BMD in a univariate analysis.^[@bibr32-2054358119858014]^ Greater BMI was associated with a better BMD.^[@bibr35-2054358119858014],[@bibr39-2054358119858014]^

### Gender {#section41-2054358119858014}

Five studies^[@bibr32-2054358119858014],[@bibr34-2054358119858014],[@bibr35-2054358119858014],[@bibr37-2054358119858014],[@bibr39-2054358119858014]^ examined the role of gender in BMD posttransplantation. Only one study^[@bibr32-2054358119858014]^ identified a baseline association between female gender and reduced lumbar and overall BMD (*P* \< .05). The other studies found no significant difference in gender with respect to change in BMD, although bone density may change differentially depending on site in males and females.^[@bibr35-2054358119858014],[@bibr37-2054358119858014]^ Alendronate increased the BMD at the lumbar spine and the hipbone in males (*P* \< .05), but only at the lumbar spine in females (*P* \< .05).^[@bibr37-2054358119858014]^ Male gender was also associated with a greater improvement in lumbar spine BMD in patients receiving osteoporosis treatment (*P* \< .01).^[@bibr35-2054358119858014]^

### Diabetes {#section42-2054358119858014}

Three studies^[@bibr32-2054358119858014],[@bibr37-2054358119858014],[@bibr39-2054358119858014]^ examined the role of diabetes in bone loss, but none investigated the duration or control of diabetes pretransplantation. One study^[@bibr32-2054358119858014]^ identified pretransplantation diabetes as an independent risk factor for low BMD (*P* \< .001), while the other 2 found a greater reduction in T-score at the lumbar spine in nondiabetic recipients (−0.52 ± 0.67 vs −0.15 ± 0.50, *P* \< .01).^[@bibr39-2054358119858014]^ Consequently, diabetes was not a significant predictive factor in BMD (OR = 0.6).^[@bibr37-2054358119858014]^

### Hemodialysis (HD) pretransplant {#section43-2054358119858014}

Only one study examined the impact of pretransplant HD duration on BMD.^[@bibr39-2054358119858014]^ The mean change reduction in T-score at the lumbar spine in the first year posttransplant was significantly greater in recipients who had been on HD for ≥12 months compared with those who had experienced dialysis \<12 months (−0.67 ± 0.79 vs −0.39 ± 0.57, *P* = .001).^[@bibr39-2054358119858014]^

### Smoking {#section44-2054358119858014}

In a multivariate analysis,^[@bibr37-2054358119858014]^ smoking was not a risk factor of BMD change posttransplantation (see [Supplemental Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2054358119858014)).

Discussion {#section45-2054358119858014}
==========

This systematic review and meta-analysis is the first to investigate the bisphosphonate effects on increasing BMD and fracture prevention beyond the first year postkidney transplantation. A recently published meta-analysis by Wang et al^[@bibr25-2054358119858014]^ demonstrated that bisphosphonate treatment in general had a beneficial effect on BMD changes at both the lumbar spine and femoral neck, which is congruent with previous studies and established practice guidelines.^[@bibr48-2054358119858014]^ Although prior studies have shown that the most rapid decrease in lumbar spine BMD occurs within the first year posttransplantation (estimated at 3%-7%), we recognize declining BMD to be a problem of longer chronicity, often confounded by several factors unique to the immediate posttransplant period.^[@bibr8-2054358119858014][@bibr9-2054358119858014][@bibr10-2054358119858014]-[@bibr11-2054358119858014],[@bibr25-2054358119858014]^

In our study, we demonstrate no statistically significant benefit of bisphosphonate treatment on BMD beyond the first year posttransplant. There was heterogeneity in studies' treatment choice and duration, but a nonsignificant improvement in lumbar spine BMD was consistently seen, while the effect appeared inconsistent in the femoral neck. Two studies^[@bibr28-2054358119858014],[@bibr39-2054358119858014]^ captured peri-transplant patients' data providing a baseline comparison, and both groups showed significant improvement with bisphosphonate treatment at the lumbar spine and femoral neck beyond 1 year posttransplant, when treatment was initiated at the time of transplantation and lasted for at least 1 year. This significant improvement persisted into the second^[@bibr28-2054358119858014],[@bibr39-2054358119858014]^ and third year^[@bibr39-2054358119858014]^ at the lumbar spine but not at the femoral neck.

As bone loss progresses beyond the first year posttransplantation,^[@bibr9-2054358119858014],[@bibr12-2054358119858014]^ we also analyzed the effects of bisphosphonates on BMD at least 12 months posttreatment initiation, regardless of the time from initial transplantation. Although bisphosphonate protocols varied widely across studies, 11 studies^[@bibr26-2054358119858014][@bibr27-2054358119858014]-[@bibr28-2054358119858014],[@bibr31-2054358119858014],[@bibr33-2054358119858014],[@bibr34-2054358119858014],[@bibr36-2054358119858014],[@bibr37-2054358119858014],[@bibr39-2054358119858014][@bibr40-2054358119858014]-[@bibr41-2054358119858014]^ identified a significant increase in BMD at 12 months posttreatment as compared with baseline.

This review demonstrated no statistically significant change in BMD beyond 1 year with bisphosphonates. Thus, the benefit of bisphosphonates may be only evident within 1 year of transplant. This is an important observation, as the protective effect may be limited to the time with highest corticosteroid dosing, and other pre- and posttransplant factors such as inflammation or bone disease. This likely indicated that there is no benefit to bisphosphonate use in renal transplant recipients beyond 1 year posttransplantation.

Despite the significant changes found with the bisphosphonate treatment at the lumbar vertebral levels, only 3 studies^[@bibr31-2054358119858014],[@bibr33-2054358119858014],[@bibr39-2054358119858014]^ displayed improvement at the femoral neck level. Although this does not translate directly to a lower fracture risk, this may extrapolate into ongoing hip fracture risks with greater protective effect at the lumbar spines in this population. This is a clinical consideration when risk-stratifying patients based on their BMD and fracture risks posttransplant. A significant limitation is that none of the studies captured fracture incidence as the sole primary outcome, likely given the paucity of fracture events.

Only one study^[@bibr38-2054358119858014]^ was able to interpret fracture results beyond reporting incidence and found no difference (HR = 0.40; 95% CI = 0.29-0.73, *P* = .001) in fracture rate after bisphosphonate treatment in their adjusted analysis.^[@bibr38-2054358119858014]^ Thus, the clinical significance of bisphosphonate therapy on patient morbidity with fracture prevention remains to be established.

Steroid use in both the early and long-term posttransplant periods has been shown to cause increased bone loss.^[@bibr37-2054358119858014]^ Specifically, prednisone doses of \>7.5 mg/d results in trabecular bone loss in most patients.^[@bibr41-2054358119858014]^ Calcineurin inhibitors have also been implicated in bone loss in animal models.^[@bibr37-2054358119858014]^ While all studies that examined steroid use reaffirmed their deleterious impact on bone health, the effect of bisphosphonates in patient populations that had received higher cumulative steroid doses was not congruent. Only Huang et al^[@bibr37-2054358119858014]^ was able to demonstrate that bisphosphonates resulted in a greater improvement in BMD at the lumbar spine in those with osteoporosis at baseline versus osteopenic patients.

Previous systematic reviews on a similar population highlighted limitations of few studies and small sample sizes. Thus, the wide scope of literature analyzed in this study sought to address this by including both observational and randomized control trials with appropriate bias analysis. A second strength of this study is our focus on long-term effectiveness of bisphosphonate treatment. It is important to recognize that the predominant population to which these data apply is well beyond the initial 12-month posttransplant and that these are the patients who carry the burden of bone disease. Our findings on bisphosphonate treatment in BMD preservation beyond 12 months posttransplant highlight limited evidence supporting the use of bisphosphonates on renal osteodystrophy.

Limitations of this review include the use of BMD as a surrogate outcome, the bias of the included studies, and the incomplete reporting data in numerous analyzed studies. The most clinically relevant outcome is the incidence of fractures. Our review assessed BMD as the primary outcome, acknowledging that BMD is not an accurate indicator of clinically meaningful patient outcomes and quality of life. Other indicators, such as bone biopsy, should be considered as a surrogate outcome in the future, keeping in mind that biopsy is expensive, invasive, and biopsy-based treatment guidelines are not yet available. We had limited information on the bone turnover state of patients to identify patients who would potentially benefit from anti-resorptive therapy. Last, we recognize that high risk of bias was identified in 44% of our included studies. We elected to include these studies given the limited sample size of the renal transplant population. The conclusions drawn from this review, however, did not change based on this bias assessment.

In conclusion, our review finds no statistical evidence for improvement in BMD in renal transplant patients beyond the first year posttransplantation with the use of bisphosphonates. We detected a differential improvement in BMD favoring the lumbar spine more so than the femoral neck, which may have clinical implications despite nonsignificance. However, the limitations of this review highlight the need for randomized control trials in patients with quantified bone turnover status evaluating fracture risk. Also quantifying other surrogate outcomes such as bone biopsy is necessary to provide more definitive evidence for the use of bisphosphates for current practice guidelines. In our future work, we plan to explore the evidence on the safety profile of bisphosphonates in this unique population with a focus on graft function. Finally, anti-resorptive and anabolic therapies are alternatives to bisphosphonates in bone mineral diseases in the general population and investigation into the use of these therapies in the renal transplant population is an avenue to further treatment options.
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